AFP and Jiji Press Announce Launch of “Fastlook” Japanese News Platform
Agence France-Presse (AFP) and Jiji Press today announced the launch of “Fastlook”, a new platform that will bring AFP’s unparalleled global news coverage to corporate and institutional clients in Japanese. This is the first collaborative service in our more than 75-year history.
Agence France-Presse (AFP) and Jiji Press today announced the launch of “Fastlook”, a new platform that will bring AFP’s unparalleled global news coverage to corporate and institutional clients in Japanese. This is the first collaborative service in our more than 75-year history.
Anglais
10/29/2025 13:00
375ai Launches Data Layer for the Physical World on Solana
375ai, an edge data intelligence company transforming the physical world into structured, machine-readable insights, today announced the launch of its mainnet on Solana. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028976994/en/375ai Launches Data Layer for the Physical World The physical world is generating more data than ever before, but most of it is invisible. Traffic systems, advertising platforms, and governments still re...
10/29/2025 13:00
GigaDevice GD32F5xx and GD32G5xx Software Test Libraries (STL) Receive TÜV Rheinland IEC 61508 Functional Safety Certification
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, announced that its GD32F5xx and GD32G5xx Software Test Libraries have received IEC 61508 SC3 (SIL 2/SIL 3) functional safety certification from TÜV Rheinland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029124621/en/Certificate This milestone expands GigaDevice’s functional safety portfolio, w...
10/29/2025 13:00
Ferring Pharmaceuticals to Explore Strategic Options for Rebyota®
As part of our ongoing transformation to sharpen our focus, we have decided to explore strategic options for Rebyota® (faecal microbiota, live – jslm). To date, more than five thousand patients suffering from recurrent Clostridioides difficile infection (rCDI) have found new hope when treated with Rebyota®. Without commercial critical mass in this therapy area at Ferring, we believe that this first-in-class, innovative product could benefit many more patients with a new approach to its continue...